Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MYD88 L265P + BRAF V600E
i
Other names:
MYD88, MYD88 Innate Immune Signal Transduction Adaptor, Myeloid Differentiation Primary Response Protein MyD88, Myeloid Differentiation Primary Response Gene (88), Myeloid Differentiation Primary Response 88, Mutant Myeloid Differentiation Primary Response 88, MYD88D, BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threon
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
673
;
4615
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
HER-2 amplification + RAS wild-type + BRAF wild-type (9)
BRAF V600K + LDH elevation (3)
BRAF V600E + MSI-H (2)
BRAF V600E + PD-L1 expression (2)
BRAF V600E + PD-L1 expression (2)
BRAF V600E + PIK3CA mutation + SMAD4 mutation + MSI-H/dMMR (2)
BRAF V600E + ROS1 fusion (2)
BRAF mutation + MET amplification (2)
BRAF mutation + MSI-L/dMMR (2)
BRAF mutation + TERT overexpression (2)
BRAF wild-type + HER-2 positive (2)
EZR overexpression + BRAF V600E (2)
IDH1 mutation + BRAF V600E (2)
IDH1 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)
IDH2 mutation + BRAF V600E (2)
IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)
MSI-H/dMMR + BRAF V600E (2)
PD-L1 expression + NRAS Q61R + BRAF D594N (2)
PD-L1 overexpression + BRAF V600E (2)
RAS wild-type + BRAF wild-type + HER-2 positive (2)
ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L (1)
ALK rearrangement + ALK I1171N + ALK V1180L + BRCA2 F2801fs (1)
BRAF E501Q + PD-L1 negative (1)
BRAF V600 + LDH elevation (1)
BRAF V600 + LDH elevation + PD-L1 negative (1)
BRAF V600E + CDKN2A deletion + MYCN amplification (1)
BRAF V600E + CDKN2A deletion + RB1 expression (1)
BRAF V600E + EGFR expression (1)
BRAF V600E + PTEN deletion (1)
BRAF V600E + SOX2 amplification (1)
BRAF V600K + CDKN2A deletion + RB1 expression (1)
BRAF mutation + PD-L1 overexpression (1)
BRAF mutation + TMB-H (1)
BRAF mutation + TMB-L + MSI-L/dMMR (1)
BRAF negative + GKAP1-NTRK2 exon 10-16 in-frame fusion (1)
BRAF wild-type + HGF elevation (1)
CD8 elevation + BRAF V600 (1)
Chr t(11;14) + BRAF mutation (1)
EGFR exon 19 deletion + BRAF G464A (1)
EGFR overexpression + BRAF V600E (1)
EGFR overexpression + BRAF mutation (1)
HER-2 amplification + BRAF wild-type (1)
HR positive + BRAF V600E (1)
KIAA1549-BRAF fusion + MET amplification (1)
KIAA1549-BRAF fusion + PTEN deletion (1)
KRAS wild-type + BRAF V600E (1)
LDH elevation + BRAF mutation (1)
MAP2K1 mutation + BRAF wild-type (1)
MSI-H/dMMR + BRAF Mutation (1)
MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)
NRAS mutation + BRAF wild-type (1)
PD-L1 expression + BRAF negative (1)
PIK3CA mutation + BRAF wild-type (1)
SEMA6A overexpression + BRAF mutation (1)
SRC overexpression + BRAF V600E (1)
TNFAIP3 overexpression + BRAF mutation (1)
MYD88 mutation + DUSP22 expression (1)
MYD88 mutation + GPER1 expression (1)
MYD88 mutation + PRDM15 expression (1)
MYD88 mutation + TNIK expression (1)
MYD88 mutation + WNK2 expression (1)
PD-L1 overexpression + BRAF mutation (0)
HER-2 amplification + RAS wild-type + BRAF wild-type (9)
BRAF V600K + LDH elevation (3)
BRAF V600E + MSI-H (2)
BRAF V600E + PD-L1 expression (2)
BRAF V600E + PD-L1 expression (2)
BRAF V600E + PIK3CA mutation + SMAD4 mutation + MSI-H/dMMR (2)
BRAF V600E + ROS1 fusion (2)
BRAF mutation + MET amplification (2)
BRAF mutation + MSI-L/dMMR (2)
BRAF mutation + TERT overexpression (2)
BRAF wild-type + HER-2 positive (2)
EZR overexpression + BRAF V600E (2)
IDH1 mutation + BRAF V600E (2)
IDH1 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)
IDH2 mutation + BRAF V600E (2)
IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)
MSI-H/dMMR + BRAF V600E (2)
PD-L1 expression + NRAS Q61R + BRAF D594N (2)
PD-L1 overexpression + BRAF V600E (2)
RAS wild-type + BRAF wild-type + HER-2 positive (2)
ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L (1)
ALK rearrangement + ALK I1171N + ALK V1180L + BRCA2 F2801fs (1)
BRAF E501Q + PD-L1 negative (1)
BRAF V600 + LDH elevation (1)
BRAF V600 + LDH elevation + PD-L1 negative (1)
BRAF V600E + CDKN2A deletion + MYCN amplification (1)
BRAF V600E + CDKN2A deletion + RB1 expression (1)
BRAF V600E + EGFR expression (1)
BRAF V600E + PTEN deletion (1)
BRAF V600E + SOX2 amplification (1)
BRAF V600K + CDKN2A deletion + RB1 expression (1)
BRAF mutation + PD-L1 overexpression (1)
BRAF mutation + TMB-H (1)
BRAF mutation + TMB-L + MSI-L/dMMR (1)
BRAF negative + GKAP1-NTRK2 exon 10-16 in-frame fusion (1)
BRAF wild-type + HGF elevation (1)
CD8 elevation + BRAF V600 (1)
Chr t(11;14) + BRAF mutation (1)
EGFR exon 19 deletion + BRAF G464A (1)
EGFR overexpression + BRAF V600E (1)
EGFR overexpression + BRAF mutation (1)
HER-2 amplification + BRAF wild-type (1)
HR positive + BRAF V600E (1)
KIAA1549-BRAF fusion + MET amplification (1)
KIAA1549-BRAF fusion + PTEN deletion (1)
KRAS wild-type + BRAF V600E (1)
LDH elevation + BRAF mutation (1)
MAP2K1 mutation + BRAF wild-type (1)
MSI-H/dMMR + BRAF Mutation (1)
MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)
NRAS mutation + BRAF wild-type (1)
PD-L1 expression + BRAF negative (1)
PIK3CA mutation + BRAF wild-type (1)
SEMA6A overexpression + BRAF mutation (1)
SRC overexpression + BRAF V600E (1)
TNFAIP3 overexpression + BRAF mutation (1)
MYD88 mutation + DUSP22 expression (1)
MYD88 mutation + GPER1 expression (1)
MYD88 mutation + PRDM15 expression (1)
MYD88 mutation + TNIK expression (1)
MYD88 mutation + WNK2 expression (1)
PD-L1 overexpression + BRAF mutation (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
MYD88 L265P + BRAF V600E
Hairy Cell Leukemia
MYD88 L265P + BRAF V600E
Hairy Cell Leukemia
rituximab
Sensitive: C4 – Case Studies
rituximab
Sensitive
:
C4
rituximab
Sensitive: C4 – Case Studies
rituximab
Sensitive
:
C4
MYD88 L265P + BRAF V600E
Non-Hodgkin’s Lymphoma
MYD88 L265P + BRAF V600E
Non-Hodgkin’s Lymphoma
rituximab
Sensitive: C4 – Case Studies
rituximab
Sensitive
:
C4
rituximab
Sensitive: C4 – Case Studies
rituximab
Sensitive
:
C4
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.